The Next Generation of Drug Discovery Platforms

DDNews features Newormics in their latest issue in a special report on drug screening

The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article titled “Phenotypic finery: Microscopy meets the molecular in the search for phenotypic impacts in drug screening”. This article reviews cutting-edge research in drug discovery using novel microscopy and image analysis technologies to screen potential drug Read more about DDNews features Newormics in their latest issue in a special report on drug screening[…]

Newormics at the 2019 UK C. elegans meeting

Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us and view our latest imaging solutions there. We will also have a special laboratory demo day, kindly hosted by Dr. Michalis Barkoulas at Imperial College London on September 17th. The demo will allow attendees to Read more about Newormics at the 2019 UK <em>C. elegans</em> meeting[…]

Introducing the Next Generation Drug Discovery Platforms

Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as 3D tissue organoids. The company provides microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions. Newormics is co-founded by Prof. Adela Read more about Introducing the Next Generation Drug Discovery Platforms[…]